<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00506129</url>
  </required_header>
  <id_info>
    <org_study_id>DM03-0279</org_study_id>
    <secondary_id>NCI-2012-01547</secondary_id>
    <nct_id>NCT00506129</nct_id>
  </id_info>
  <brief_title>Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma</brief_title>
  <official_title>Study of Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma (CTCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to see if receiving a transplant of blood stem&#xD;
      cells (cells that can produce blood) or bone marrow from either a related donor (brother,&#xD;
      sister or other relative) or an unrelated voluntary donor will help patients with advanced&#xD;
      cutaneous T-cell lymphoma. The length of time that patients who receive the treatment remain&#xD;
      free of disease will also be studied.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      You will receive the chemotherapy drug fludarabine for 5 days (Days 1 to 5). The drug&#xD;
      melphalan will be given on Days 4 and 5. You may also receive the drug anti-thymocyte&#xD;
      globulin (ATG) on Days 4, 5, 6. This will be followed by infusion of blood stem cells or bone&#xD;
      marrow from a donor on Day 7. A separate consent will be provided to the donor. The donor can&#xD;
      be a brother, sister or another family member or a compatible unrelated donor. The drugs and&#xD;
      the stem cells will be given through a catheter (a small tube) placed under the collarbone.&#xD;
      You may receive your treatment on an inpatient or outpatient basis. If treated on an&#xD;
      inpatient basis, you will stay in the hospital during treatment and recovery, which can take&#xD;
      4 to 5 weeks even if there are no complications.&#xD;
&#xD;
      The chemotherapy and the ATG are given to help the body accept the transplanted stem cells or&#xD;
      bone marrow. You will receive antibiotics to fight infection and a medicine called G-CSF&#xD;
      (NeupogenÂ®) to help blood counts rise back to healthier levels. G-CSF is given as an&#xD;
      injection under the skin. You will also need blood and platelet transfusions.&#xD;
&#xD;
      You will be given standard drugs to help decrease the risk of side effects. You may ask the&#xD;
      study staff for information about how the drugs are given and their risks.&#xD;
&#xD;
      If the cancer grows and graft-versus-host disease is not present, you may be eligible to&#xD;
      receive donor blood cells (lymphocytes) infused through the catheter. This may cause&#xD;
      graft-versus-host disease and may help shrink the cancer. If the cancer grows and&#xD;
      graft-versus-host disease is already present, then donor lymphocytes are not given.&#xD;
&#xD;
      Sometimes, the body rejects the donor cells; this reaction is called &quot;graft rejection&quot;.&#xD;
      Sometimes the donor cells attack the body, a reaction called graft-versus-host disease&#xD;
      (GvHD). The drugs tacrolimus and methotrexate will be given to help prevent these reactions&#xD;
      from occurring. These drugs are given through a vein or by mouth before and/or after the&#xD;
      transplant.&#xD;
&#xD;
      You must stay in the Houston area for at least 100 days after the transplant. After 100 days,&#xD;
      you must return to Houston every 3 months for 2 years for tests and checkups, then once a&#xD;
      year for at least 3 years. If there is no sign of lymphoma growth at the follow up visit(s),&#xD;
      you will receive no further treatment.&#xD;
&#xD;
      This is an investigational study. The drugs used in this study are approved by the FDA and&#xD;
      are commercially available. As many as 35 patients will take part in the study. All will be&#xD;
      enrolled at MD Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participant's Response According to Physician's Global Assessment of Clinical Condition (PGA)</measure>
    <time_frame>Response assessed pre-transplant and 100 days post transplant with follow up at 1 year.</time_frame>
    <description>Response defined by Physician's Global Assessment of Clinical Condition (PGA) where Complete Response (CR) is No evidence of disease; 100% improvement; Partial Response (PR), one of following: 1) Very significant clearance ( &gt; 90% to &lt; 100%); only traces of disease remains; 2) Significant improvement ( &gt; 75% to &lt; 90%); some evidence of disease remain; 3) Intermediate between slight and marked improvement; ( &gt; 50% to &lt; 75%); 4) Some improvement ( &gt; 25% to &lt; 50%); however, significant evidence of disease remains; Stable Disease (SD): Disease has not changed from baseline condition (+&lt;25%); Progressive Disease (PD): Disease is worse than at baseline evaluation by &gt; 25% or more. Response confirmed by a second assessment at least 4 weeks following it. Assessments at baseline, pre and post transplant (100 days) then till disease progression or year one.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average Overall Survival (OS) Length</measure>
    <time_frame>Baseline to disease progression, followed up to 5 years post transplant</time_frame>
    <description>OS was defined as the time from transplantation to the date of death from any cause or last follow up, measured in days.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Lymphoma</condition>
  <condition>Disorder Related to Bone Marrow Transplantation</condition>
  <arm_group>
    <arm_group_label>Fludarabine + Melphalan with PBPC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fludarabine 25 mg/m^2 intravenous (IV) daily for 5 Days prior to Allogeneic Transplant, Melphalan 70 mg/m^2 IV daily for 2 Days prior to IV Allogeneic Transplant following Fludarabine &amp; Melphalan. Thymoglobulin 2 mg/kg/day IV on days -3, -2 &amp; -1 for patients receiving matched unrelated marrow/stem cells or mismatched related marrow.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>25 mg/m^2 Given By Vein Daily for 5 Days Prior to Allogeneic Transplant.</description>
    <arm_group_label>Fludarabine + Melphalan with PBPC</arm_group_label>
    <other_name>Fludarabine Phosphate</other_name>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>70 mg/m^2 Given By Vein Daily for 2 Days Prior to Allogeneic Transplant.</description>
    <arm_group_label>Fludarabine + Melphalan with PBPC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Transplant</intervention_name>
    <description>Allogeneic transplant given by vein after completion of Fludarabine and Melphalan.</description>
    <arm_group_label>Fludarabine + Melphalan with PBPC</arm_group_label>
    <other_name>Allogeneic peripheral blood progenitor cell</other_name>
    <other_name>PBPC</other_name>
    <other_name>Bone Marrow transplantation</other_name>
    <other_name>Stem Cell Transplant</other_name>
    <other_name>SCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoglobulin</intervention_name>
    <description>2 mg/kg/day by vein on days -3, -2 and -1 for patients receiving matched unrelated marrow/stem cells or mismatched related marrow.</description>
    <arm_group_label>Fludarabine + Melphalan with PBPC</arm_group_label>
    <other_name>ATG</other_name>
    <other_name>Antithymocyte Globulin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with pathologically proven cutaneous T-cell lymphoma (CTCL), disease stage&#xD;
             IIB to IVB, patients must be in at least a partial response-PR (skin and lymph nodes)&#xD;
             after receiving other non-allogeneic transplant therapy, age &lt;/= 70 years, Zubrod&#xD;
             performance status 0 or 1, left ventricular ejection fraction &gt;/= 50% or approved for&#xD;
             transplant by a cardiologist, DLCO &gt;/= 50% predicted or approved for transplant by a&#xD;
             pulmonologist, serum creatinine &lt;/= 1.5 mg/dL, serum bilirubin &lt; 2mg/dL. SGPT &lt; 3 x&#xD;
             upper limit of normal, and no previous history of allogeneic transplantation.&#xD;
&#xD;
          2. Donor: HLA-compatible related (HLA-A, -B, -DRB1 matched or with one-antigen mismatch)&#xD;
             or HLA-compatible unrelated (HLA-A, -B, -C and -DRB1 matched or with one-antigen&#xD;
             mismatch).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1) Patients cannot have active central nervous system (CNS) disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chitra M. Hosing, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>July 20, 2007</study_first_submitted>
  <study_first_submitted_qc>July 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2007</study_first_posted>
  <results_first_submitted>June 30, 2016</results_first_submitted>
  <results_first_submitted_qc>December 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 29, 2020</results_first_posted>
  <last_update_submitted>December 3, 2020</last_update_submitted>
  <last_update_submitted_qc>December 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cutaneous T-Cell Lymphoma</keyword>
  <keyword>CTCL</keyword>
  <keyword>Allogeneic Transplantation</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Allogeneic peripheral blood progenitor cell</keyword>
  <keyword>PBPC</keyword>
  <keyword>Bone Marrow transplantation</keyword>
  <keyword>Stem Cell Transplant</keyword>
  <keyword>SCT</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>Fludarabine Phosphate</keyword>
  <keyword>Fludara</keyword>
  <keyword>Melphalan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: September 26, 2003 to November 05, 2012. All recruitment done at The University of Texas MD Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Fludarabine + Melphalan With PBPC</title>
          <description>Fludarabine 25 mg/m^2 intravenous (IV) daily for 5 days prior to allogeneic peripheral blood progenitor cell (PBPC) , Melphalan 70 mg/m^2 IV daily for 2 days prior to IV Allogeneic Transplant following Fludarabine &amp; Melphalan. Thymoglobulin 2 mg/kg/day IV on days -3, -2 &amp; -1 for patients receiving matched unrelated marrow/stem cells or mismatched related marrow.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Disease Progression/Relapse</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fludarabine + Melphalan With PBPC</title>
          <description>Fludarabine 25 mg/m^2 intravenous (IV) daily for 5 days prior to allogeneic peripheral blood progenitor cell (PBPC) , Melphalan 70 mg/m^2 IV daily for 2 days prior to IV Allogeneic Transplant following Fludarabine &amp; Melphalan. Thymoglobulin 2 mg/kg/day IV on days -3, -2 &amp; -1 for patients receiving matched unrelated marrow/stem cells or mismatched related marrow.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" lower_limit="20" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participant's Response According to Physician's Global Assessment of Clinical Condition (PGA)</title>
        <description>Response defined by Physician's Global Assessment of Clinical Condition (PGA) where Complete Response (CR) is No evidence of disease; 100% improvement; Partial Response (PR), one of following: 1) Very significant clearance ( &gt; 90% to &lt; 100%); only traces of disease remains; 2) Significant improvement ( &gt; 75% to &lt; 90%); some evidence of disease remain; 3) Intermediate between slight and marked improvement; ( &gt; 50% to &lt; 75%); 4) Some improvement ( &gt; 25% to &lt; 50%); however, significant evidence of disease remains; Stable Disease (SD): Disease has not changed from baseline condition (+&lt;25%); Progressive Disease (PD): Disease is worse than at baseline evaluation by &gt; 25% or more. Response confirmed by a second assessment at least 4 weeks following it. Assessments at baseline, pre and post transplant (100 days) then till disease progression or year one.</description>
        <time_frame>Response assessed pre-transplant and 100 days post transplant with follow up at 1 year.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fludarabine + Melphalan With PBPC</title>
            <description>Fludarabine 25 mg/m^2 intravenous (IV) daily for 5 days prior to allogeneic peripheral blood progenitor cell (PBPC) , Melphalan 70 mg/m^2 IV daily for 2 days prior to IV Allogeneic Transplant following Fludarabine &amp; Melphalan. Thymoglobulin 2 mg/kg/day IV on days -3, -2 &amp; -1 for patients receiving matched unrelated marrow/stem cells or mismatched related marrow.</description>
          </group>
        </group_list>
        <measure>
          <title>Participant's Response According to Physician's Global Assessment of Clinical Condition (PGA)</title>
          <description>Response defined by Physician's Global Assessment of Clinical Condition (PGA) where Complete Response (CR) is No evidence of disease; 100% improvement; Partial Response (PR), one of following: 1) Very significant clearance ( &gt; 90% to &lt; 100%); only traces of disease remains; 2) Significant improvement ( &gt; 75% to &lt; 90%); some evidence of disease remain; 3) Intermediate between slight and marked improvement; ( &gt; 50% to &lt; 75%); 4) Some improvement ( &gt; 25% to &lt; 50%); however, significant evidence of disease remains; Stable Disease (SD): Disease has not changed from baseline condition (+&lt;25%); Progressive Disease (PD): Disease is worse than at baseline evaluation by &gt; 25% or more. Response confirmed by a second assessment at least 4 weeks following it. Assessments at baseline, pre and post transplant (100 days) then till disease progression or year one.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response (CR) Converted Post Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CR Prior to Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease (SD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease (PD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Overall Survival (OS) Length</title>
        <description>OS was defined as the time from transplantation to the date of death from any cause or last follow up, measured in days.</description>
        <time_frame>Baseline to disease progression, followed up to 5 years post transplant</time_frame>
        <population>Baseline to disease progression, followed up to 5 years post transplant (assess at 100 days, every 3 months for 2 years, then once a year for at least 3 years)</population>
        <group_list>
          <group group_id="O1">
            <title>Fludarabine + Melphalan With PBPC</title>
            <description>Fludarabine 25 mg/m^2 intravenous (IV) daily for 5 days prior to allogeneic peripheral blood progenitor cell (PBPC) , Melphalan 70 mg/m^2 IV daily for 2 days prior to IV Allogeneic Transplant following Fludarabine &amp; Melphalan. Thymoglobulin 2 mg/kg/day IV on days -3, -2 &amp; -1 for patients receiving matched unrelated marrow/stem cells or mismatched related marrow.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Overall Survival (OS) Length</title>
          <description>OS was defined as the time from transplantation to the date of death from any cause or last follow up, measured in days.</description>
          <population>Baseline to disease progression, followed up to 5 years post transplant (assess at 100 days, every 3 months for 2 years, then once a year for at least 3 years)</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1207" lower_limit="17" upper_limit="1825"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events collected till 30 days following end of active treatment (the date of the stem cell infusion).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Fludarabine + Melphalan With PBPC</title>
          <description>Fludarabine 25 mg/m^2 intravenous (IV) daily for 5 days prior to allogeneic peripheral blood progenitor cell (PBPC) , Melphalan 70 mg/m^2 IV daily for 2 days prior to IV Allogeneic Transplant following Fludarabine &amp; Melphalan. Thymoglobulin 2 mg/kg/day IV on days -3, -2 &amp; -1 for patients receiving matched unrelated marrow/stem cells or mismatched related marrow.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>neutropenic fever</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Primary graft failure with autologous reconstitution</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Cardiac Edema</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Cardiac Function</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Congestive heart failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>pericarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>mucositis</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="32" subjects_affected="32" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal disorder, GvHD</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>vomit</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>fluid overload: Edema</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>rigors</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>abdomen pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>transaminitis</sub_title>
                <description>Elevated transaminases alanine transaminase (ALT) and aspartate transaminase (AST)</description>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection</sub_title>
                <counts group_id="E1" events="37" subjects_affected="17" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Acute Graft versus Host Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>increase T bilirubin</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>weakness, generalized</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>muscular wasting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>myalgias</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>bone pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>drowsiness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>bladder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>renal failure</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>frequency, urine</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>hemorrhagic cystitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Acute Kidney Disease (renal disorder), dialysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>dysuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pulmonary edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>pleural effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>hiccoups</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>pneumonitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>shortness of breath</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chitra M. Hosing, Professor, Stem Cell Transplantation</name_or_title>
      <organization>University of Texas (UT) MD Anderson Cancer Center</organization>
      <phone>1-877-MDA-6789</phone>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

